Market Access News | pharmaphorum

News

UK politicians to grill Vertex CEO over CF price drug row

The CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating the ongoing row over the price of cystic fibrosis drugs in England

News

Napp launches Neulasta biosimilar in UK

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following

News

Bayer completes US filing for prostate cancer drug darolutam...

Bayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible approval later this year and a market clash with Pfizer/Astellas a

News

Pharma CEOs grilled by US Senators over drug prices

Pharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription drugs in the US compared with other developed countries.

News

Catalyst defends huge US price hike for rare disease drug

Catalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to more than $300,000 per year following criticism from Senat

News

Final NICE rejection for Biomarin's childhood rare disease d...

After a year of negotiations NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease drug, saying that the company is unable to address concerns about long-term ef

UK politicians to grill Vertex CEO over CF price drug row

Napp launches Neulasta biosimilar in UK

Bayer completes US filing for prostate cancer drug darolutam...

Pharma CEOs grilled by US Senators over drug prices

Catalyst defends huge US price hike for rare disease drug

Final NICE rejection for Biomarin's childhood rare disease d...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks